Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?

Journal of the National Cancer Institute

Volumn 94, Issue 11, 2002, Pages 805-818

  Parmiani, Giorgio ^a   Castelli, Chiara ^a   Dalerba, Piero ^a   Mortarini, Roberta ^a   Rivoltini, Licia ^a   Marincola, Francesco M ^b   Anichini, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA INTERFERON; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MELAN A; MELANOMA ANTIGEN; MELANOMA VACCINE; MEMBRANE ANTIGEN; MONOPHENOL MONOOXYGENASE; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTASIS INHIBITION; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN CONFORMATION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; VACCINE PRODUCTION;

EID: 0037024461     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.11.805     Document Type: Review

References (148)

1. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semi-allogeneic system
2. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
3. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
4. A listing of human tumor antigens recognized by T cells
5. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
6. MHC restriction in three dimensions: A view of T cell receptor/ligand interactions
7. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
8. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
9. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene
10. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
11. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene
12. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocytes (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
13. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene
14. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival
15. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
16. Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
17. Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells
18. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells
19. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules
20. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
21. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
22. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides
23. Tumor regression observed in patients with metastatic melanoma treated with an antigen peptide encoded by gene MAGE-3 and presented by HLA-A1
24. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
25. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
26. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
27. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: Implication in the identification of cryptic tumor epitopes
28. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: Implications for optimization of antigen presentation and tumor-specific CTL induction
29. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines
30. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL
31. Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of Tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide
32. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy
33. Structural and functional consequences of altering a peptide MHC anchor residue
34. Amino acid substitutions in the melanoma antigen recognized by T cell 1 peptide modulate cytokine responses in melanoma-specific T cells
35. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells
36. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln→Leu61)
37. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201
38. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription
39. Degradation of cell proteins and the generation of MHC class I-presented peptides
40. The sequence alteration associated with a mutational hot spot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope
41. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
42. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer
43. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients
44. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer
45. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not immune surveillance in metastatic lesions
46. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype
47. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
48. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
49. A shift in the phenotype of Melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
50. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
51. Human neoplasms elicit multiple immune responses in the autologous host
52. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
53. Identification of NY-ESO-1 epitopes presented by human histocompatibility (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
54. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
55. Peptide-induced antiviral protection by cytotoxic T cells
56. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide
57. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides
58. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells
59. The makings of a tumor rejection antigen
60. Protective antitumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads protein
61. An HLA-A2 polyepitope vaccine for melanoma immunotherapy
62. Tolerance
63. T cell priming versus T cell tolerance induced by synthetic peptides
64. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
65. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
66. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells
67. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo
68. The role of CpG motifs in innate immunity
69. The dendritic cell and human cancer vaccines
70. Adoptive T cell therapy of tumors, mechanisms operative in the recognition and elimination of tumor cells
71. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
72. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells
73. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor
74. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
75. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
76. Three different vaccines based on the 140-amino acid muc1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus muc1-transgenic mice with tumor rejection
77. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration
78. Dendritic cells injected via different routes induce immunity in cancer patients
79. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors
80. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
81. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state
82. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
83. Differentiation of T regulatory cells by immature dendritic cells
84. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
85. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
86. Cloning of the gene coding for a shared antigen recognized by autologous T cells infiltrating into tumor
87. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
88. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
89. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
90. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
91. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma
92. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
93. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
94. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony stimulating factor in patients with metastatic melanoma
95. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
96. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous this mutation
97. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma
98. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
99. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells
100. Vaccination of patients with chronic myelogenous leukemia with ber-abl oncogene breakpoint fusion peptides specific immune responses
101. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
102. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy
103. Dendritic cells in cancer immunotherapy
104. Autologous dendritic cells for treatment of advanced cancer-an update
105. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
106. Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity
107. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine
108. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
109. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
110. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
111. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide
112. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
113. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
114. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papilloma virus type 16-transformed cells
115. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
116. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world
117. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
118. Human HSP70 peptide complexes specifically activate anti-melanoma T cells
119. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study
120. Clinical and immunological results of vaccination with autologous heat-shock protein peptide complex-96 (HSPPC-96) in metastatic melanoma
121. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
122. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
123. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
124. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide
125. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance
126. In vivo tracking of tumor-specific T cells
127. Clinical significance of decreased alpha chain expression in peripheral blood lymphocytes of patients with head and neck cancer
128. Where have all the T cells gone? Mechanisms of immune evasion by tumors
129. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
130. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions
131. Status of activation of circulating vaccine-elicited CD8+ T cells
132. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients
133. Clonal expansion of T lymphocytes in human melanoma metastases after treatment
134. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
135. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens
136. Phenotypic analysis of antigen-specific T lymphocytes
137. Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells
138. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: Association with disease progression
139. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines
140. Short term kinetics of tumor antigen expression in response to vaccination
141. Not so fas: Re-evaluating the mechanisms of immune privilege and tumor escape
142. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing
143. Cytokines and immune response in the tumor microenvironment
144. A natural history of melanoma: Serial gene expression analysis
145. Tumors as elusive targets of immunotherapy
146. CD4 T cells and their role in antitumor immune responses
147. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles
148. On the probability of effective anticancer vaccines